東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Bayesian optimal design for phase II...

Ding, Meichun.

FindBook

Google Book

Amazon

博客來

Bayesian optimal design for phase II screening trials.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Bayesian optimal design for phase II screening trials./
作者:	Ding, Meichun.
面頁冊數:	89 p.
附註:	Adviser: Gary L. Rosner.
Contained By:	Dissertation Abstracts International67-05B.
標題:	Biology, Biostatistics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3216696
ISBN:	9780542678615

Bayesian optimal design for phase II screening trials.
Ding, Meichun.

Bayesian optimal design for phase II screening trials. - 89 p.

Adviser: Gary L. Rosner.

Thesis (Ph.D.)--Rice University, 2006.

Rapid progress in biomedical research necessitates clinical evaluation that identifies promising innovations quickly and efficiently. Rapid evaluation is especially important if the number of innovations is large compared to the supply of suitable study patients. Most phase II screening designs available in the literature consider one treatment at a time. Each study is considered in isolation. We propose a more systematic decision-making approach to the phase II screening process. The sequential study design allows for more efficiency and greater learning about treatments. The approach incorporates a Bayesian hierarchical model that allows combining information across several related studies in a formal way and improves estimation in small data sets by borrowing strength from other treatments. The underlying probability model is a hierarchical probit regression model that also allows for treatment-specific covariates. The design criterion is to maximize the utility for the new treatment, a sampling cost per patient, and the possible demonstration of a significant treatment benefit in a future randomized clinical trial. Computer simulations show that, this method has high probabilities of discarding treatments with low success rates and moving treatments with high success rates to phase III trial. Compared to the fully sequential design proposed by Wang and Leung's in 1998 Biometrics, this method provides a smaller number of patients required to screen out the first promising treatment and has better design characteristics.

ISBN: 9780542678615Subjects--Topical Terms:

1018416
Biology, Biostatistics.

Bayesian optimal design for phase II screening trials.
LDR:02397nam 2200277 a 45 001 968819
005 20110920
008 110921s2006 eng d
020 $a 9780542678615
035 $a (UnM)AAI3216696
035 $a AAI3216696
040 $a UnM $c UnM
100 1 $a Ding, Meichun. $3 1292877
245 1 0 $a Bayesian optimal design for phase II screening trials.
300 $a 89 p.
500 $a Adviser: Gary L. Rosner.
500 $a Source: Dissertation Abstracts International, Volume: 67-05, Section: B, page: 2639.
502 $a Thesis (Ph.D.)--Rice University, 2006.
520 $a Rapid progress in biomedical research necessitates clinical evaluation that identifies promising innovations quickly and efficiently. Rapid evaluation is especially important if the number of innovations is large compared to the supply of suitable study patients. Most phase II screening designs available in the literature consider one treatment at a time. Each study is considered in isolation. We propose a more systematic decision-making approach to the phase II screening process. The sequential study design allows for more efficiency and greater learning about treatments. The approach incorporates a Bayesian hierarchical model that allows combining information across several related studies in a formal way and improves estimation in small data sets by borrowing strength from other treatments. The underlying probability model is a hierarchical probit regression model that also allows for treatment-specific covariates. The design criterion is to maximize the utility for the new treatment, a sampling cost per patient, and the possible demonstration of a significant treatment benefit in a future randomized clinical trial. Computer simulations show that, this method has high probabilities of discarding treatments with low success rates and moving treatments with high success rates to phase III trial. Compared to the fully sequential design proposed by Wang and Leung's in 1998 Biometrics, this method provides a smaller number of patients required to screen out the first promising treatment and has better design characteristics.
590 $a School code: 0187.
650 4 $a Biology, Biostatistics. $3 1018416
650 4 $a Statistics. $3 517247
690 $a 0308
690 $a 0463
710 2 0 $a Rice University. $3 960124
773 0 $t Dissertation Abstracts International $g 67-05B.
790 $a 0187
790 1 0 $a Rosner, Gary L., $e advisor
791 $a Ph.D.
792 $a 2006
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3216696